Aurobindo Pharma Ltd

Aurobindo Pharma Ltd

₹ 1,208 1.63%
28 Jun - close price
About

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)

Key Points

Leading Pharmaceutical company [1]
Aurobindo Pharma is India’s second-largest pharma company & Largest generics company in the US (by Rx dispensed). It is also the largest generic company in the US and is amongst the top 10 generic companies in seven out of 11 countries in Europe.[2]The Company is among the top 5 listed pharmaceutical companies in India by FY22 revenues [3]

  • Market Cap 70,758 Cr.
  • Current Price 1,208
  • High / Low 1,292 / 709
  • Stock P/E 37.2
  • Book Value 337
  • Dividend Yield 0.37 %
  • ROCE 11.6 %
  • ROE 10.1 %
  • Face Value 1.00

Pros

  • Company has reduced debt.
  • Company has been maintaining a healthy dividend payout of 25.5%

Cons

  • Stock is trading at 3.59 times its book value
  • The company has delivered a poor sales growth of -2.78% over past five years.
  • Company has a low return on equity of 8.81% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
4,114 2,894 2,883 2,623 2,887 1,742 1,948 2,361 2,406 2,391 2,669 2,692 2,894
3,138 2,483 2,543 2,407 2,380 1,529 1,680 1,917 1,830 1,968 2,124 2,210 2,119
Operating Profit 976 411 340 216 507 213 268 444 576 422 545 482 775
OPM % 24% 14% 12% 8% 18% 12% 14% 19% 24% 18% 20% 18% 27%
267 44 82 131 339 38 36 54 326 113 103 331 123
Interest 6 5 3 4 5 6 12 25 32 32 37 61 53
Depreciation 124 115 98 101 101 56 61 60 67 60 66 64 65
Profit before tax 1,113 335 320 242 740 189 231 413 804 444 546 687 780
Tax % 22% 36% 38% 1% -8% 35% 29% 28% 20% 24% 24% 9% 26%
873 215 198 240 802 122 165 299 645 336 416 624 579
EPS in Rs 14.89 3.67 3.37 4.09 13.69 2.08 2.81 5.10 11.01 5.73 7.10 10.65 9.88
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
5,424 7,108 8,069 9,158 9,607 10,270 12,258 13,371 15,824 11,287 12,792 10,646
4,462 5,187 5,816 6,705 7,215 7,600 9,838 10,670 11,704 9,783 11,061 8,422
Operating Profit 961 1,922 2,253 2,453 2,392 2,670 2,420 2,700 4,120 1,504 1,731 2,224
OPM % 18% 27% 28% 27% 25% 26% 20% 20% 26% 13% 14% 21%
23 73 65 187 118 81 189 386 590 565 434 670
Interest 250 289 132 229 45 53 231 243 29 17 115 183
Depreciation 171 186 245 263 286 355 413 473 488 415 435 255
Profit before tax 563 1,519 1,940 2,148 2,179 2,343 1,965 2,370 4,193 1,637 1,614 2,457
Tax % 12% 23% 22% 24% 22% 23% 22% 21% 26% 11% 24% 20%
496 1,172 1,516 1,627 1,707 1,813 1,530 1,877 3,113 1,455 1,230 1,954
EPS in Rs 8.52 20.11 25.96 27.80 29.13 30.94 26.11 32.03 53.13 24.83 21.00 33.35
Dividend Payout % 9% 7% 9% 9% 9% 8% 10% 9% 8% 36% 36% 4%
Compounded Sales Growth
10 Years: 4%
5 Years: -3%
3 Years: -12%
TTM: -17%
Compounded Profit Growth
10 Years: 5%
5 Years: 4%
3 Years: -15%
TTM: 56%
Stock Price CAGR
10 Years: 12%
5 Years: 15%
3 Years: 8%
1 Year: 66%
Return on Equity
10 Years: 15%
5 Years: 12%
3 Years: 9%
Last Year: 10%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 29 29 29 59 59 59 59 59 59 59 59 59
Reserves 2,910 3,983 5,330 6,807 8,378 9,924 11,292 12,994 15,866 17,059 17,856 19,664
2,782 2,925 3,285 4,165 3,054 3,719 4,520 3,741 4,042 1,895 4,203 2,861
1,103 1,638 1,582 1,534 1,533 2,092 2,270 2,770 3,222 2,589 2,816 2,570
Total Liabilities 6,825 8,576 10,226 12,566 13,023 15,794 18,141 19,564 23,189 21,601 24,934 25,154
2,012 1,938 2,190 2,568 3,212 3,393 4,150 4,418 4,472 3,586 3,688 2,419
CWIP 166 204 227 742 907 1,144 789 815 735 225 239 133
Investments 708 873 1,013 1,183 1,682 1,968 2,339 2,527 5,010 6,584 8,222 13,393
3,938 5,561 6,796 8,072 7,222 9,289 10,863 11,804 12,972 11,206 12,785 9,209
Total Assets 6,825 8,576 10,226 12,566 13,023 15,794 18,141 19,564 23,189 21,601 24,934 25,154

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
625 328 590 1,185 2,457 922 530 2,201 2,995 3,727 1,821 1,715
-295 -401 -624 -1,390 -1,542 -991 -1,301 -948 -2,650 -1,615 -3,459 -160
-229 -31 35 515 -1,329 440 599 -1,255 -28 -2,448 1,719 -1,837
Net Cash Flow 101 -105 1 310 -414 371 -171 -1 316 -335 81 -282

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 116 153 168 175 143 159 156 158 137 128 130 129
Inventory Days 174 179 207 207 191 273 235 242 244 210 219 148
Days Payable 109 130 111 109 96 130 109 107 104 130 117 112
Cash Conversion Cycle 181 202 264 273 239 301 282 293 277 208 232 166
Working Capital Days 167 182 208 220 197 236 242 234 208 241 202 162
ROCE % 15% 29% 27% 24% 20% 19% 15% 16% 23% 9% 8%

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
51.83% 51.83% 51.83% 51.83% 51.83% 51.84% 51.84% 51.84% 51.84% 51.84% 51.84% 51.84%
23.70% 21.71% 21.37% 20.83% 20.71% 21.41% 22.31% 23.03% 24.12% 22.45% 20.72% 18.01%
14.66% 15.52% 16.49% 17.47% 17.30% 16.56% 14.90% 15.09% 15.73% 18.29% 20.60% 23.28%
9.80% 10.93% 10.31% 9.86% 10.15% 10.20% 10.96% 10.06% 8.31% 7.43% 6.85% 6.87%
No. of Shareholders 2,43,3153,29,9403,41,5683,38,6393,59,6843,58,4593,69,8283,43,6172,93,2142,59,6382,41,9442,44,575

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls